Simplifying Software Security: Veracode Enhances Frictionless Experience for Developers
14.9.2022 21:33:00 EEST | Business Wire | Press release
Black Hat (booth #2428) – Veracode, a leading global provider of application security testing solutions, today announced the enhancement of its Continuous Software Security Platform with substantial improvements to its integrated developer experience. New features include extended integrations to support software composition analysis (SCA), a software bill of materials (SBOM) Application Programming Interface (API), and additional language and framework support for static analysis, further enhancing developers’ ability to secure software in the environments where they work.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005141/en/
Fig. 1 Veracode “Beat the Heat” security flaw heat map, State of Software Security Report v12 (Graphic: Business Wire)
Brian Roche, Chief Product Officer at Veracode, said, “Modern applications are mostly assembled, not written from scratch. Open-source code makes up a significant proportion of audited code bases—for example, 97 percent of the typical Java application is made up of open-source libraries*—increasing security risk and the need to identify supply chain risk. Our SBOM API, is designed to make it easier for developers to inventory their code base, including third-party components, allowing them to act quickly if new vulnerabilities emerge. Since the launch of our Continuous Software Security Platform in May, we have introduced additional capabilities that meet developers right where they work: in the integrated developer environment (IDE), code repository, and command line interface. These innovations are designed to drive adoption by making the platform even more developer friendly.”
Facilitating DevSecOps
Veracode’s platform supports 100+ languages and frameworks, including those for cloud-native application development and older languages used with legacy assets, like COBOL. Large enterprises have applications across myriad languages and being able to deploy a continuous security testing solution across them simplifies the process, while providing consistent results. The company’s latest State of Software Security (SoSS) 12 research analyzed the most common flaws by language and revealed that a prevalent flaw for one language may not be of any concern for another. For example, cross-site scripting (XSS) is the most common flaw for PHP, at 77 percent, but doesn’t even make the top 10 for C++*. Moreover, flaws change constantly, meaning that even if a flaw isn’t prevalent in a programming language, practitioners should still take active steps to prevent it from impacting their code. Since remediation tactics vary by flaw and programming language, having a broad array of language support in one place makes developers’ jobs easier by freeing up their time to focus on meeting tight deployment deadlines.
Frequent scanning of first- and third-party code mitigates the risk from both proprietary and open-source vulnerabilities, such as Log4j. Veracode’s new developer-centric tools and services are designed to make this a quicker and easier process, particularly with the additional capability of third-party proprietary library scanning.
Peter Evans, Engineering Director at QAD Precision GTTE, said, “Veracode brought a complete platform for us to build security tools into our development pipelines, as well as helped us grow our knowledge to keep getting better at security. Veracode was also a good fit because the platform can scan Java code in the Spring framework where we develop our software. We’ve gone from reviewing code to integrating continuous scans into our daily pipelines. Security threats don’t stand still and Veracode provides us the tools to keep up with the latest vulnerabilities and rules.”
Notable updates to the Veracode Continuous Software Security platform include:
SBOM for SCA
- With government regulations driving standards for securing software supply chains, having an SBOM is increasingly important for organizations. Veracode’s SBOM API in SCA enables developers to easily generate an SBOM in CycloneDX JSON format—one of the approved formats for compliance with the U.S. Executive Order. This helps confirm the code they’re using, or building, is free from vulnerabilities.
IDE and Integrations for SCA
To make software security a seamless experience, Veracode continues to introduce integrations that meet developers where they work.
- The Veracode Azure DevOps Extension has a new “SCA Flaw Importer” to automatically import SCA flaws into Azure DevOps Boards and Work Items
- The soon-to-be-released Veracode for Visual Studio Code extension provides detailed information on vulnerabilities, licence risks, and recommended versions of open-source libraries and transitive dependencies so developers can rapidly respond to any risks
Expanded Frameworks and Languages Support for Static Analysis
- The company is committed to keeping up with the latest language and frameworks with which developers work, adding support for Rails 7.0, Ruby 3.x, and PHP Symfony
Roche concluded, “As a pioneer of application security, we are uniquely positioned to combine unrivalled experience with the latest innovations in cloud development. Unlike on-premise vendors, our SaaS solution is both scalable and elastic, meaning customers are always prepared to meet unexpected demand. Powered by nearly two decades of cumulative data, our platform provides detailed comparative historical reviews against industry benchmarks and peers—a level of insight highly relevant for leadership teams and the board. Our platform also saves developers time by delivering highly accurate results and enabling them to find and fix vulnerabilities in minutes, meaning they can ship code quickly with the confidence that it is secure.”
Developers can learn more about Veracode’s platform, the frictionless developer experience, and how to simply and maturely secure their SDLC by visiting Veracode’s booth #2428 at Black Hat USA.
*Veracode State of Software Security Report v12, February 2022
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.
Learn more at www.veracode.com, on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220809005141/en/
Contact information
Press and Media
Katy Gwilliam
Head of Global PR, Veracode
kgwilliam@veracode.com
+44.7584.341.110
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release
Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom